GenePOC proud to announce $5.7 million GAPP partnership to support development and commercialization of two new tests on its POC platform

GenePOC Inc., a Canadian company developing cost-effective and rapid molecular devices to detect pathogen genes at Point-of-Care, is pleased to announce that its project, in partnership with Université Laval, was successful in securing funding from Genome Canada and Génome Québec through the Genomic Applications Partnership Program (GAPP).

The project, entitled “New test to rapidly diagnose infections”, aims to support the development and commercialization of two new tests for the rapid diagnostic of infections. The GAPP program partners academic researchers with “users” of genomics to support projects that address real world challenges and opportunities.

“This funding from the Canadian government provides an opportunity for GenePOC to leverage the broad genomic expertise from the labs of Dr Michel G. Bergeron” said Patrice Allibert, PhD, CEO GenePOC. “ The first two assays developed by GenePOC, namely Group B Strep (GBS) and Clostridium Difficile (C.diff.), are scheduled to enter clinical trials validation within the next weeks. This project will help accelerate the development of our assay menu and will increase the attractiveness of our offer.”

Click here to read the detailed press release and background information from Genome Canada.

Click here to read the press release from Génome Québec

Canada’s GenePOC Expanding to Enter Lab and POC MDx Market Next Year

NEW YORK (from GenomeWeb – Madeleine Johnson) – Canadian firm GenePOC recently expanded its staff and intends to enter the molecular diagnostics market with a Group B Streptococcus assay at the end of the second quarter of 2016 and a Clostridium difficile assay in Q4 2016.

The company will initially launch the tests as CE-IVD products in Europe, and is aiming for US Food and Drug Administration approval of its platform and assays in late 2016.

To support these efforts, GenePOC received an undisclosed amount of private financing at the beginning of this year. Swiss development group Debiopharm Diagnostics is now the largest shareholder in GenePOC, with Montreal’s Emerillon Capital also providing investment.

“Since then, the company is progressing very rapidly,” Herbert Torfs, vice president of business development strategy, told GenomeWeb in an interview.

Read the full article >

Download a PDF version of the full article >

A Quebec City company on the cusp of a revolution in the field of medical diagnosis

A Quebec City company on the cusp of a revolution in the field of medical diagnosis

Infectious disease diagnosis made fast and easy with GenePOC technology

Quebec City, February 11th, 2015 – It will soon be possible to diagnose and identify Clostridium difficile, Staphylococcus, Streptococcus, respiratory tract infections, sexually transmitted infections, and a variety of other infectious diseases much faster using cutting edge technology developed by GenePOC, a rapidly expanding Quebec City company.

Not only will it be much simpler to diagnose and identify the infectious agent, but there will also be a tremendous impact on patient health. The time period between a visit to a healthcare professional and the start of appropriate medical treatment will be reduced to an absolute minimum.

“We have perfected a technology that can detect pathogen genes right at the point of care. The screening tests we offer are truly a revolution in medicine, particularly in the field of infectious disease diagnosis,” explains Patrice Allibert, CEO of the company located in the Quebec Metro High Tech Park.

Entirely designed and developed in the provincial capital at the CHU Québec by teams led by Dr. M. G. Bergeron, this technology meets a real and urgent need. “Health specialists around the world need a fast, high-quality diagnostic tool to help them provide targeted treatment for infectious diseases and provide patients with the best possible care,” says Sébastien Chapdelaine, Vice President, R&D. “This is a big improvement in health care, because the GenePOC device can provide results in under an hour, which means patients can start getting treatment sooner,” adds Allibert.

About GenePOC

Winner of the 2013 North America Frost & Sullivan Entrepreneurial Company of the Year Award in molecular diagnostics, GenePOC is experiencing strong growth. The company recently expanded its office space from 8,000 square feet to 15,000 square feet and is set to double its staff in the coming year. Some 20 new employees will join its current team of professionals to develop and launch this product on the market.

 

-30-

Source and information:

 

Veronique Chayer

Senior Advisor

Rouillier Communication Marketing

[email protected]

418-780-5391, ext. 2203

A revolutionary microfluidic stand-alone platform (GenePOC) for nucleic-acid based point-of-care diagnostics

GenePOC  in Global Point of Care, Strategies for Disasters, complex emergencies, and Public Health crises: Enhancing Standards of care at the site of need. AACC Press, Washington, DC, Kost G and C Corbin (eds)

Bissonnette L, S Chapdelaine, R Peytavi, A Huletsky, G Stewart, M Boissinot, P Allibert, and MG Bergeron (2014). A revolutionary microfluidic stand-alone platform (GenePOC) for nucleic-acid based point-of-care diagnostics. pp 235-247

See the full text

GenePOC is now installed in its new State of the Art facility

GenePOC is now located in the Technological Park in Quebec City. The State of the Art facility is equiped with ISO 7 clean rooms to install  the molecular development of assays and the manufacturing of its disposable.

GenePOC, 360 Rue Franquet, Suite #100, Québec G1P 4N3, Canada